About Innocoll

Innocoll is a specialty pharmaceutical company committed to improving the status quo and finding answers to unmet needs

XARACOLL® (bupivacaine HCl) Implant

Our lead product, XARACOLL, was approved by the U.S. Food and Drug Administration in August 2020

Latest News

Innocoll Announces Commercial Launch of XARACOLL® (bupivacaine HCI) implant, a Non-opioid, Drug-device Treatment Option for Acute Postsurgical Pain Relief for up to 24 Hours Following Open Inguinal Hernia Repair in Adults

First-in-class, fully bioresorbable, collagen implant delivers postsurgical pain relief directly to the surgical site ATHLONE, Ireland, Oct. 29, 2020 /PRNewswire/ -- Innocoll Holdings Limited,...
Read More

Innocoll to Partner with Mallinckrodt Acute Care Sales Team to Support the Launch of XARACOLL® (bupivacaine HCl) implant

Mallinckrodt’s hospital sales force to begin promoting recently approved XARACOLL®, a first-of-its-kind, fully bioresorbable collagen implant that delivers bupivacaine HCI...
Read More

FDA Approves XARACOLL® (bupivacaine HCl) Implant, a Non-opioid, Drug-device Treatment Option for Acute Postsurgical Pain Relief for up to 24 Hours Following Open Inguinal Hernia Repair in Adults

XARACOLL is a first-of-its-kind, fully bioresorbable collagen implant that delivers bupivacaine HCl directly to the surgical site providing long-lasting pain...
Read More